SGLT2 inhibitors serve as foundational, disease-modifying therapies for Cardiovascular-Kidney-Metabolic syndrome requiring proactive, multidisciplinary coordination for optimal management.
Expert perspective emphasizes proactive, multidisciplinary management of CKM syndrome with SGLT2 inhibitors as foundational therapy.
Absolute Event Rate: 0% vs 0%
Shifting from reactive to proactive CKM management requires an integrated care model aligning specialties around early, organ-protective interventions. SGLT2i should be recognized as foundational, disease-modifying therapy, supported by multidisciplinary coordination, clear clinical algorithms, and patient-centered communication.
Avogaro et al. (Thu,) reported a other. SGLT2 inhibitors serve as foundational, disease-modifying therapies for Cardiovascular-Kidney-Metabolic syndrome requiring proactive, multidisciplinary coordination for optimal management.